Comirnaty (Note 2) (monovalent, Original) Partial Change Approval
Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2) (active ingredient: tozinameran)
Approval Information
Brand NameComirnaty (Note 2)
(monovalent, Original)
Partial Change Approval
Generic NameCoronavirus Modified Uridine RNA Vaccine (SARS-CoV-2)
(active ingredient: tozinameran)
ApprovedNovember 2021
TypeInitial Approval
Review Reports
Want structured data, translation summaries & alerts?
PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.
Join the WaitlistSource: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.